Enrollment complete in the replicate REDUCE 1 and REDUCE 2 Phase 3 studies with pivotal data expected in Q2 2026 SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback